A group of scientists report that the gene FKBPL can predict whether women with breast cancer will respond to tamoxifen. They say that when it is found in high levels in breast cancer, it indicates a good response to tamoxifen and a better chance of survival. Conversely low levels of FKBPL indicate a poor response.
The study was led by Tracy Robson, Ph.D., and Hayley McKeen, Ph.D., from the School of Pharmacy Queen’s University Belfast. Their findings are published in Cancer Research in a paper titled “FKBPL Regulates Estrogen Receptor Signaling and Determines Response to Endocrine Therapy.”